神经药理学报 ›› 2024, Vol. 14 ›› Issue (1): 28-.DOI: 10.3969/j.issn.2095-1396.2024.01.005

• 研究论文 • 上一篇    下一篇

舒必利片联合鲁拉西酮片对精神分裂症患者精神症状、认知功能和血清催乳素水平的影响

黄河,倪圣梅,吴玉凤   

  1. 1. 福建省南平市第三医院精神科,南平,353000,中国 

    2. 福建省南平市第三医院五病区,南平,353000,中国 

    3. 福建省南平市第三医院检验科,南平,353000,中国

  • 出版日期:2024-02-26 发布日期:2024-05-24
  • 作者简介:黄河,学士,副主任医师;研究方向:精神分裂症,焦虑障碍;E-mail: huanghe0925@126.com
  • 基金资助:
    南平市科技计划项目(No.N2013Y05)

Effects of Sulpiride Tablets Combined with Lurasidone Tablets on Mental Symptoms, Cognitive Function and Serum Prolactin Levels in Patients with Schizophrenia

HUANG He, NI Sheng-mei, WU Yu-feng   

  1. 1. Department of Psychiatry, Third Hospital of Nanping City, Nanping, 353000, China 

    2. Fifth Ward of the Third Hospital of Nanping City, Nanping, 353000, China 

    3. Laboratory of the Third Hospital of Nanping City, Nanping, 353000, China

  • Online:2024-02-26 Published:2024-05-24

摘要:

目的:探讨舒必利片联用鲁拉西酮片对精神分裂症的治疗效果。方法:精神分裂症患者80 例随机 分为对照组40 例与观察组40 例,对照组予舒必利片治疗,观察组予舒必利片联用鲁拉西酮片,两组均治疗8 周。评价两组治疗效果,比较两组精神症状、认知功能[ 可重复成套神经心理状态测量(repeatable battery for the assessment of neuropsychological status, RBANS)]、社会功能[ 个人和社会功能量表(personal and social performance scale, PSP)] 及血清催乳素(serum prolactin, PRL)水平在治疗前、后的变化,并统计不良反应。结果: 观察组总有效率为95.00%,与对照组(75.00%)进行比较显著增高(P<0.05)。治疗后,观察组相比对照组精神症 状评分更低,RBANS 评分、PSP 评分均显著增高(P<0.05)。治疗后,两组血清PRL 均显著增高(P<0.05),组间不 具有统计学差异(P>0.05)。不良反应发生率对比,相比对照组,观察组未见明显增加(P>0.05)。结论:精神分裂 症患者在舒必利片治疗基础上,联用鲁拉西酮片可提高疗效,改善患者认知功能,且对血清PRL 无明显影响,安 全性良好。

关键词: 精神分裂症, 舒必利, 鲁拉西酮, 认知功能, 催乳素

Abstract:

Objective:To investigate the therapeutic effect of sulpiride tablets combined with lurasidone tablets on schizophrenia. Methods: 80 patients with schizophrenia were randomly divided into control group (n=40) and observation group (n=40), they were treated with sulpiride tablets and sulpiride tablets combined with lurasidone tablets respectively. Both groups were treated for 8 weeks. The therapeutic effects of the two groups were evaluated. The changes of mental symptoms, cognitive function [Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)], social function [Personal and Social Performance Scale (PSP)] and serum prolactin (PRL) levels before and after treatment were compared between the two groups, and the adverse reactions were counted. Results: Comparing with the control group (75.00%), the total effective rate of treatment in the observation group (95.00%) was higher(P<0.05). After treatment, the mental symptom score of the observation group was lower, and the RBANS score and PSP score were significantly higher comparing with the control group(P<0.05). After treatment, the serum PRL of the two groups increased significantly(P<0.05), and the difference between the two groups shows no significant (P>0.05). Compared with the control group, there was no significant increase in the incidence of adverse reactions in the observation group (P>0.05). Conclusion: On the basis of sulpiride tablets, the combination of lurasidone tablets in patients with schizophrenia can improve the efficacy and cognitive function of patients, and has no significant effect on serum PRL, with good safety.

Key words: schizophrenia, sulpiride, lurasidone, cognitive function, prolactin